Multi-country clinic network with 150+ facilities across Northern Europe
Bergman Clinics Germany operates 16 sites across dermatology, ophthalmology, orthopedics, and aesthetic medicine, treating ~237,000 patients annually. The tech stack is heavily Microsoft-dependent (Dynamics NAV, Power Platform, Active Directory), reflecting a healthcare operator's focus on administrative integration rather than innovation velocity. Hiring remains concentrated in clinical roles (43 of 55 active positions), with finance and support functions scaling to absorb M&A activity — active projects in M&A financial modeling and company integration signal the network is in acquisition-driven expansion mode.
Bergman Clinics Germany is part of a larger Scandinavian and Benelux clinic network founded in the late 1980s with over 150 facilities across the Netherlands, Sweden, Denmark, Norway, and Germany. The German operation runs 16 clinics staffed by 1,160+ employees, including 210 physicians, and specializes in high-volume outpatient care across four medical verticals. Current strategic focus centers on nationwide dermatology network expansion, M&A integration, and operational professionalization — particularly in financial reporting systems, quality assurance processes, and lab services buildout.
Primary tools include Dynamics NAV (ERP), Power Platform (Power BI, Power Apps, Power Automate), Active Directory, Jira, and LucaNet. Stack reflects administrative integration needs across a multi-site healthcare operator.
Approximately 237,000 patients per year across 16 clinic locations, with staffing of 1,160+ employees including 210 physicians.
Bergman Clinics Germany's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.